CJC-1295 (without DAC): Research Peptide Guide

For research purposes only. This guide describes the chemical identity and laboratory handling of CJC-1295 and summarises findings reported in published research. It is not medical advice and does not describe any effect, dose, or use in humans or animals.

What is CJC-1295?

CJC-1295 without DAC (also known as Modified GRF 1-29 / Mod GRF 1-29) is a synthetic 29-amino-acid analogue of growth hormone-releasing hormone (GHRH), with amino-acid substitutions that improve stability relative to the native sequence. It is supplied as a lyophilised powder for research.

PurePeptides offers CJC-1295 (without DAC) at >99% purity strictly for in-vitro research use. This page describes its chemical identity and handling only.

The “without DAC” distinction matters. The with-DAC form carries a Drug Affinity Complex that binds serum albumin to greatly extend its half-life; the without-DAC form studied here — Modified GRF (1-29) — does not. Relative to the native GHRH (1-29) sequence, the amino-acid substitutions in Modified GRF (1-29) are reported in the literature to improve resistance to enzymatic breakdown while preserving activity at the GHRH receptor.

Chemical identity & specifications

Handling CJC-1295 in research protocols

In laboratory settings, lyophilised CJC-1295 is typically stored at -20°C, protected from light and moisture, until use. For reconstitution, bacteriostatic water is a commonly cited solvent; once in solution, the material is generally kept refrigerated at 2-8°C with freeze-thaw cycles minimised to preserve peptide integrity.

Researchers quantify CJC-1295 by concentration within their experimental system — for example molar concentrations for in-vitro work, or amount-per-mass figures in animal models. These are parameters defined by the study design and reported in the literature; they are not dosing guidance for any human or animal use. To convert between vial mass, solvent volume, and target concentration for laboratory preparation, our peptide reconstitution calculator may be useful.

Findings reported in the research literature

Modified GRF (1-29) is built on the N-terminal 1-29 fragment of growth hormone-releasing hormone, long established in endocrine research as the shortest sequence that retains GHRH-receptor activity. The substituted CJC-1295 (without DAC) analogue appears in GHRH-analogue research as a more enzymatically stable variant used in in-vitro and preclinical studies.

Any effects described in this literature are observations made in controlled experimental systems — cell assays and animal models — and are reported here only to summarise the scientific record. They do not constitute claims about outcomes, efficacy, benefits, or safety in humans, and nothing on this page should be read as encouraging human or animal use. Readers interested in the primary research can review the indexed literature via PubMed’s CJC-1295 results.

The GHRH-analogue family: how CJC-1295 compares

CJC-1295 is studied alongside other peptides in growth-hormone-axis research. The GHRH analogues share a receptor target but differ in sequence and length; ipamorelin is included below for contrast as a ghrelin / GHS-receptor ligand:

Sermorelin, CJC-1295 (without DAC) and tesamorelin all act at the GHRH receptor, which distinguishes them from ghrelin / GHS-receptor ligands such as ipamorelin (see our separate ipamorelin guide). All of these peptides are supplied by PurePeptides strictly as research materials, with no claim regarding outcomes in humans or animals.

Purity and quality control in research-grade CJC-1295

In laboratory research, peptide purity has a direct bearing on reproducibility: synthesis by-products or residual reagents can confound experimental observations. PurePeptides supplies CJC-1295 at greater than 99% purity as a lyophilised powder.

In peptide manufacturing, purity is typically assessed by reverse-phase high-performance liquid chromatography (HPLC), while identity is confirmed by mass spectrometry (MS) against the expected molecular weight — approximately 3368.7 g/mol for CJC-1295. A certificate of analysis (COA) documenting these results is available on request for the current batch. When evaluating any research-grade peptide, requesting the COA and confirming both the purity figure and the mass-spec identity is good laboratory practice.

Frequently asked questions

Research-grade CJC-1295

Greater than 99% purity, lyophilised powder, same-day dispatch before 3PM with tracked UK & EU delivery. Research use only.

Disclaimer: All products supplied by PurePeptides are strictly for laboratory research use only. They are not for human or animal consumption and are not medical products. This guide is informational and summarises publicly available research; it is not medical, clinical, or dosing advice.